On the development of computational tools for the modelling and simulation of SCWO process intensified by hydrothermal flames

El objetivo de esta tesis es mejorar el entendimiento de las llamas hidrotermales en el proceso de oxidación en agua supercrítica (OASC), desarrollando herramientas para su modelado y simulación. Este conocimiento es necesario para los avances en la utilización del proceso OASC como un proceso de generación de energía. En el capítulo 1 se revisa el estado del arte de la tecnología, con especial atención a la producción de energía. Se remarcan las necesidades de investigación en propiedades de mezclas supercríticas y en equipos de expansión. En los capítulos 2, 3 y 4 se presentan los métodos de estimación de propiedades y los modelos cinéticos desarrollados y su eficiencia en la descripción de los datos experimentales. El error en la predicción de propiedades y cinéticas es de 5% y 11%, respectivamente. En los capítulos 5 y 6 el modelo es aplicado a un nuevo reactor OASC. El reactor se describe correctamente y las simulaciones indican que el proceso podría funcionar de forma auto-temáticaDepartamento de Ingeniería Química y Tecnología del Medio Ambient

Pretreatment Processes of Biomass for Biorefineries: Current Status and Prospects

Producción CientíficaThis article seeks to be a handy document for the academy and the industry to get quickly up to speed on the current status and prospects of biomass pretreatment for biorefineries. It is divided into two biomass sources: vegetal and animal. Vegetal biomass is the material produced by plants on land or in water (algae), consuming sunlight, CO2, water, and soil nutrients. This includes residues or main products from, for example, intensive grass crops, forestry, and industrial and agricultural activities. Animal biomass is the residual biomass generated from the production of food from animals (e.g., manure and whey). This review does not mean to include every technology in the area, but it does evaluate physical pretreatments, microwave-assisted extraction, and water treatments for vegetal biomass. A general review is given for animal biomass based in physical, chemical, and biological pretreatments

Formic acid production by simultaneous hydrothermal CO2 reduction and conversion of glucose and its derivatives

Producción CientíficaBackground: The hydrothermal reduction of CO2 using organic molecules such as alcohols can produce renewable fuels and platform chemicals, such as formic acid (FA). If the process is performed using glucose as reductant, the yield is especially high, because FA is selectively produced both by reduction of CO2 and by degradation of glucose degradation in alkaline hydrothermal media. Methods: This article analyzes the origin of formic acid using NaH13CO3 as CO2 source, assisted by HPLC and 13C-NMR to study the origin of FA. Significant findings: Results show that two reactions pathways take place: the first one, at short reaction times, consists on the decomposition of glucose into formic acid and other by-products, achieving low yield to FA-13C, whereas longer reaction times lead to a higher yield to FA-13C. Similarly, temperature plays an important role, being 300°C the optimal. Further reactions were performed using the main by-products of previous reactions (acetic acid, lactic acid, glycolaldehyde and glyceraldehyde) as reductants to understand the reaction mechanisms. Results indicate that the reduction pathway of NaHCO3 take place by oxidation of the by-products rather than by the oxidation of glucose itself, needing long reaction times to achieve significant high ratios of FA-13C/ total FA.Junta de Andalucía - Fondo Europeo de Desarrollo Regional (project CLU-2019-04)Ministerio de Ciencia, Innovación y Universidades (projects RTI2018-097456-B-I00 and PGC2018-099470-B-I00

Supercritical water oxidation for energy production by hydrothermal flame as internal heat source. Experimental results and energetic study

Producción CientíficaThe cooled wall reactor has been modified by adding an additional upper outlet of products at 500–700 °C to improve energy recovery and make possible energy generation with the supercritical water oxidation of different waste. Experimental and modeling results of the performance of this new reactor configuration are presented as well as a theoretical analysis of the energy recovery of the reactor compared to other supercritical water oxidation reactors. Different flow distributions were tested to find the best elimination conditions. Total organic carbon removal over 99.99% was obtained at room injection temperatures, when the fraction of products leaving the reactor in the upper effluent is lower than 70% of feed flow. The performance of the reactor was tested with the oxidation of a recalcitrant compound such as ammonia. Removals higher than 99% of were achieved at temperatures near 700 °C. The behavior of the reactor working with feeds with up to 2.5% wt Na2SO4 could be injected in the reactor without plugging problems. Upper effluent always presented a concentration of salt lower than 30 ppm. Theoretical energetic analysis shows that the performance of this reactor is superior to other designs obtaining a maximum power efficiency of 27% (0.339 kW/kg-feed).Ministerio de Economía, Industria y Competitividad - FEDER (Proyect CTQ2013-44143-R

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Latent heat loss of dairy cows in an equatorial semi-arid environment

The present study aimed to evaluate evaporative heat transfer of dairy cows bred in a hot semi-arid environment. Cutaneous (E (S)) and respiratory (E (R)) evaporation were measured (810 observations) in 177 purebred and crossbred Holstein cows from five herds located in the equatorial semi-arid region, and one herd in the subtropical region of Brazil. Rectal temperature (T (R)), hair coat surface temperature (T (S)) and respiratory rate (F (R)) were also measured. Observations were made in the subtropical region from August to December, and in the semi-arid region from April to July. Measurements were done from 1100 to 1600 hours, after cows remained in a pen exposed to the sun. Environmental variables measured in the same locations as the animals were black globe temperature (T (G)), air temperature (T (A)), wind speed (U), and partial air vapour pressure (P (V)). Data were analysed by mixed models, using the least squares method. Results showed that average E (S) and E (R) were higher in the semi-arid region (117.2 W m(-2) and 44.0 W m(-2), respectively) than in the subtropical region (85.2 W m(-2) and 30.2 W m(-2), respectively). Herds and individual cows were significant effects (P < 0.01) for all traits in the semi-arid region. Body parts did not affect T (S) and E (S) in the subtropical region, but was a significant effect (P < 0.01) in the semi-arid region. The average flank T (S) (42.8A degrees C) was higher than that of the neck and hindquarters (39.8A degrees C and 41.6A degrees C, respectively). Average E (S) was higher in the neck (133.3 W m(-2)) than in the flank (116.2 W m(-2)) and hindquarters (98.6 W m(-2)). Coat colour affected significantly both T (S) and E (S) (P < 0.01). Black coats had higher T (S) and E (S) in the semi-arid region (41.7A degrees C and 117.2 W m(-2), respectively) than white coats (37.2A degrees C and 106.7 W m(-2), respectively). Rectal temperatures were almost the same in both subtropical and semi-arid regions. The results highlight the need for improved management methods specific for semi-arid regions.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES